OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Orexigen Therapeutics, Inc. Exhibit
EX-99.1 2 d465862dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation,…
To view the full exhibit click here

About OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX)

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.